HC Wainwright Issues Positive Forecast for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price

06 Mar 2026, 05:56 by Scott Moore · The Cerbat Gem

Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) had its price objective hoisted by HC Wainwright from $4.00 to $6.00 in a research report sent to investors on Thursday morning, MarketBeat.com reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $4.63.

Read Our Latest Report on Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Stock Performance

Shares of Lexicon Pharmaceuticals stock opened at $1.64 on Thursday. Lexicon Pharmaceuticals has a one year low of $0.32 and a one year high of $1.83. The company has a market cap of $596.09 million, a price-to-earnings ratio of -8.63 and a beta of 0.94. The business’s 50 day moving average price is $1.35 and its 200 day moving average price is $1.33. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.63 and a current ratio of 5.64.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. The firm had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $3.14 million. On average, research analysts predict that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Insider Buying and Selling at Lexicon Pharmaceuticals

In other news, Director Raymond Debbane bought 100,000 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were purchased at an average price of $1.47 per share, with a total value of $147,000.00. Following the purchase, the director owned 1,904,186 shares in the company, valued at approximately $2,799,153.42. The trade was a 5.54% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Invus Global Management, Llc bought 1,538,462 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were purchased at an average price of $1.30 per share, with a total value of $2,000,000.60. Following the completion of the acquisition, the director directly owned 1,538,462 shares in the company, valued at $2,000,000.60. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have bought 1,790,462 shares of company stock valued at $2,369,981. Company insiders own 13.90% of the company’s stock.

Institutional Trading of Lexicon Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in shares of Lexicon Pharmaceuticals in the fourth quarter valued at approximately $42,000. Invesco Ltd. lifted its holdings in Lexicon Pharmaceuticals by 14.1% during the 4th quarter. Invesco Ltd. now owns 594,883 shares of the biopharmaceutical company’s stock worth $684,000 after buying an additional 73,480 shares in the last quarter. Millennium Management LLC boosted its position in Lexicon Pharmaceuticals by 25.9% in the 4th quarter. Millennium Management LLC now owns 4,821,733 shares of the biopharmaceutical company’s stock valued at $5,545,000 after buying an additional 991,073 shares during the period. Ishara Investments LP acquired a new position in shares of Lexicon Pharmaceuticals in the fourth quarter worth $1,012,000. Finally, ExodusPoint Capital Management LP purchased a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth $309,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals News Summary

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

Positive Sentiment: Q4 results beat expectations: GAAP EPS of -$0.04 beat consensus by $0.03 and revenue of $5.49M topped estimates by roughly $2.35M — a near-term fundamental beat that often lifts sentiment for small-cap biotechs. Earnings Beat Article
Positive Sentiment: Company reiterated key clinical progress: sotagliflozin milestones remain on schedule (including planned NDA resubmission in T1D) and SONATA HCM enrollment is underway — these program milestones reduce clinical execution risk and can unlock future value. GlobeNewswire Q4 & Clinical Update
Positive Sentiment: Pilavapadin pathway validated by a positive End-of-Phase 2 FDA meeting, supporting Phase 3 readiness and potential partnership discussions — increases likelihood of collaboration or licensing deals that could provide non-dilutive funding or milestones. Pilavapadin EOP2 Note
Positive Sentiment: Balance sheet strengthened: company said it secured >$100M in additional cash from a capital raise plus a Novo Nordisk milestone payment — lowers near-term dilution/financing risk and funds clinical programs. Cash Raise & Milestone
Positive Sentiment: Analyst upgrade/target lift: H.C. Wainwright raised its price target from $4 to $6 and maintained a Buy — a sizable upside thesis that can attract momentum buyers and retail interest. HC Wainwright PT Raise
Neutral Sentiment: Management hosted a conference call and published slides and a transcript — useful for investors who want detail on timelines, cash burn and partnering strategy but not an immediate price catalyst by itself. Q4 Slide Deck
Negative Sentiment: Company remains unprofitable with a steep negative net margin (~96.8%) and negative ROE; street estimates project a full-year loss (consensus ~ -$0.66) — long-term value still hinges on clinical success or deal-making. Financials & Estimates

About Lexicon Pharmaceuticals

(Get Free Report)

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.